After losing ground in commercial clinical trials in recent years, the UK has now turned a corner and is once again taking a ...

Nanoelectronics specialist Imec will demonstrate a miniaturised, ingestible sensor device today that can monitor ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...

Guidance on the new policy from the Department for Science, Innovation and Technology (DSIT) notes that qualifying for ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade ...

Early access programmes (EAPs) for novel medicines are an often-misunderstood strategy outside of western markets. In a new ...

The US has been at the centre of a shift in global trade dynamics these last few weeks, resulting from a rise in geopolitical ...

23andMe was founded 19 years ago to provide saliva-based genetic testing of health and ancestry to consumers, going public in ...

The partner of former Theranos founder and chief executive Elizabeth Holmes, Billy Evans, has reportedly raised millions of ...

BioMarin has been resetting its business with cuts in headcount and a narrowing of active programmes over the last year or so ...

With the FDA and EMA releasing their annual reports detailing novel drug approvals in 2024, a new pharmaphorum podcast looks ...